Notably, administering a CXCR2 (the receptor for CXCL1 and CXCL2) blocking antibody resulted in reduced accumulation of PMN–MDSCs in the colon and subsequently prevented tumor development in inducible models of colitis-associated cancer [129]. Here, CXCL2 is linked to neoplasm.